SG10201903658QA - Personalized anti-cancer agent screening system - Google Patents
Personalized anti-cancer agent screening systemInfo
- Publication number
- SG10201903658QA SG10201903658QA SG10201903658QA SG10201903658QA SG10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer agent
- cancer
- screening system
- personalized
- agent screening
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 11
- 238000012216 screening Methods 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120143573A KR101327533B1 (ko) | 2012-12-11 | 2012-12-11 | 환자 맞춤형 항암제 선별용 시스템 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201903658QA true SG10201903658QA (en) | 2019-05-30 |
Family
ID=49857311
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201903658QA SG10201903658QA (en) | 2012-12-11 | 2013-12-11 | Personalized anti-cancer agent screening system |
SG11201504628UA SG11201504628UA (en) | 2012-12-11 | 2013-12-11 | Personalized anti-cancer agent screening system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201504628UA SG11201504628UA (en) | 2012-12-11 | 2013-12-11 | Personalized anti-cancer agent screening system |
Country Status (9)
Country | Link |
---|---|
US (3) | US20160103119A1 (es) |
EP (1) | EP2933636B1 (es) |
JP (3) | JP2016501027A (es) |
KR (1) | KR101327533B1 (es) |
CN (1) | CN104919315B (es) |
ES (1) | ES2886512T3 (es) |
SA (1) | SA113350064B1 (es) |
SG (2) | SG10201903658QA (es) |
WO (1) | WO2014092457A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101782005B1 (ko) * | 2015-05-28 | 2017-09-27 | 한국과학기술원 | 암미세환경 어레이 플랫폼 |
KR102557289B1 (ko) * | 2016-01-27 | 2023-07-20 | 연세대학교 산학협력단 | 미만형 종양의 환자 유래 이종이식 모델 및 이의 제조방법 |
KR101983547B1 (ko) * | 2016-04-04 | 2019-05-29 | 주식회사 싸이토젠 | 단기배양 혈중 암세포(ctc)를 활용한 개인 맞춤형 항암제 선별시스템 및 선별방법 |
KR101895207B1 (ko) * | 2016-05-12 | 2018-09-07 | 주식회사 싸이토젠 | 환자 유래 체액 종양세포를 활용한 맞춤형 항암제 선별방법 |
CA3026236C (en) * | 2016-06-03 | 2021-01-26 | Samsung Life Public Welfare Foundation | Method for screening antibody using patient-derived tumor spheroids |
IT201700004017A1 (it) * | 2017-01-16 | 2018-07-16 | React4Life Srl | Bioreattore e metodo di utilizzo di detto bioreattore |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
SG11202010129WA (en) * | 2018-04-13 | 2020-11-27 | Shanghai Lide Biotech Co Ltd | Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screening anti-tumor drugs |
CN108624561B (zh) * | 2018-05-26 | 2021-09-17 | 复旦大学 | 原代肿瘤细胞培养基、培养方法以及应用 |
CN115862890B (zh) * | 2022-08-31 | 2023-08-11 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种抗癌药物筛选方法及系统 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424209A (en) * | 1993-03-19 | 1995-06-13 | Kearney; George P. | Automated cell culture and testing system |
US9342657B2 (en) | 2003-03-24 | 2016-05-17 | Nien-Chih Wei | Methods for predicting an individual's clinical treatment outcome from sampling a group of patient's biological profiles |
WO2005014856A1 (en) * | 2003-08-08 | 2005-02-17 | Canbas Co., Ltd. | Sensitivity test to predict efficacy of anti-cancer therapies |
KR100689107B1 (ko) * | 2004-05-25 | 2007-03-09 | 가톨릭대학교 산학협력단 | 세포독성 분석법과 결합된 다층 암세포 배양계를 이용한항암물질의 활성 측정 방법 |
JP2006166799A (ja) * | 2004-12-16 | 2006-06-29 | Motoko Iijima | 抗癌剤選択検査方式 |
CA2652434A1 (en) * | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
CN101313221A (zh) * | 2005-09-21 | 2008-11-26 | Ccc诊断有限责任公司 | 用于个人化抗癌化疗(pac)的综合诊断检测方法 |
CA2623445A1 (en) | 2005-09-21 | 2007-03-29 | Ccc Diagnostics, Llc | Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac) |
EP1792978A1 (en) * | 2005-12-01 | 2007-06-06 | Stiftung Caesar Center of Advanced European Studies and Research | Means and methods for the isolation and characterization of cancer stem cells |
US20080113390A1 (en) | 2006-08-08 | 2008-05-15 | In Suk Han | Personalized assay for the identification of an effective therapy for cancer |
EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
KR101046883B1 (ko) * | 2008-11-19 | 2011-07-06 | 재단법인 아산사회복지재단 | 항암제 치료약제에 대한 감수성을 일괄적으로 결정하는 방법 |
AR076590A1 (es) | 2009-05-19 | 2011-06-22 | Vivia Biotech Sl | Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos |
JP2011115106A (ja) * | 2009-12-04 | 2011-06-16 | Rei Medical Co Ltd | 癌細胞凝集塊およびその調製法 |
JP5809782B2 (ja) * | 2009-12-24 | 2015-11-11 | 株式会社ルネッサンス・エナジー・インベストメント | 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法 |
CN103250176A (zh) * | 2010-08-13 | 2013-08-14 | 智能医学公司 | 用于生产个性化定制药物产品的系统和方法 |
KR101371697B1 (ko) | 2011-02-07 | 2014-03-07 | 연세대학교 원주산학협력단 | 환자 맞춤형 암 치료 |
WO2012138785A1 (en) * | 2011-04-04 | 2012-10-11 | Nestec Sa | Methods for predicting and improving the survival of gastric cancer patients |
US20140047570A1 (en) * | 2011-04-19 | 2014-02-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Animal model of human cancer and methods of use |
-
2012
- 2012-12-11 KR KR20120143573A patent/KR101327533B1/ko active IP Right Grant
-
2013
- 2013-12-10 SA SA113350064A patent/SA113350064B1/ar unknown
- 2013-12-11 ES ES13863563T patent/ES2886512T3/es active Active
- 2013-12-11 WO PCT/KR2013/011490 patent/WO2014092457A1/ko active Application Filing
- 2013-12-11 US US14/651,207 patent/US20160103119A1/en not_active Abandoned
- 2013-12-11 SG SG10201903658QA patent/SG10201903658QA/en unknown
- 2013-12-11 CN CN201380070033.7A patent/CN104919315B/zh active Active
- 2013-12-11 EP EP13863563.6A patent/EP2933636B1/en active Active
- 2013-12-11 JP JP2015547851A patent/JP2016501027A/ja active Pending
- 2013-12-11 SG SG11201504628UA patent/SG11201504628UA/en unknown
-
2017
- 2017-05-15 JP JP2017096417A patent/JP2017195887A/ja active Pending
-
2019
- 2019-05-08 JP JP2019088305A patent/JP6867431B2/ja active Active
- 2019-12-06 US US16/705,492 patent/US20200110071A1/en not_active Abandoned
-
2023
- 2023-02-24 US US18/113,713 patent/US20230213501A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2886512T3 (es) | 2021-12-20 |
SA113350064B1 (ar) | 2016-04-05 |
CN104919315A (zh) | 2015-09-16 |
JP6867431B2 (ja) | 2021-04-28 |
JP2016501027A (ja) | 2016-01-18 |
EP2933636A1 (en) | 2015-10-21 |
US20230213501A1 (en) | 2023-07-06 |
KR101327533B1 (ko) | 2013-11-08 |
US20200110071A1 (en) | 2020-04-09 |
JP2019150043A (ja) | 2019-09-12 |
WO2014092457A1 (ko) | 2014-06-19 |
SG11201504628UA (en) | 2015-07-30 |
JP2017195887A (ja) | 2017-11-02 |
EP2933636B1 (en) | 2021-07-07 |
US20160103119A1 (en) | 2016-04-14 |
EP2933636A4 (en) | 2017-03-22 |
CN104919315B (zh) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201903658QA (en) | Personalized anti-cancer agent screening system | |
IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12014501844A1 (en) | Peptidomimetic macrocycles | |
MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
EP2739337A4 (en) | ARRANGEMENTS, SYSTEMS AND METHOD FOR INFUSING THERAPEUTICS IN THE BODY | |
WO2014167126A3 (en) | Platform for targeted delivery to stem cells and tumor cells and uses thereof | |
MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
EP2859898A4 (en) | THERAPEUTIC AGENT, METHOD OF TREATMENT AND TESTING METHOD FOR DISEASES ASSOCIATED WITH ACTIVATION OF NEUTROPHILIC GRANULOCYTES | |
MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
WO2014005153A3 (en) | Methods for treating mds1-evi1 mediated cancer | |
SG11201808253YA (en) | Marker for predicting treatment response to anti-cancer agent in solid cancer patients | |
SG10201908587PA (en) | Treatment regimens | |
PH12014502464A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
MX2012000952A (es) | Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica. | |
MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
WO2012139021A3 (en) | TARGETING HK alpha FOR CONTROLLING BLOOD PRESSURE AND REGULATING ELECTROLYTE BALANCE | |
LV14615A (lv) | Līdzeklis karbonila olbaltumvielu līmeņa pazemināšanai asins plazmā | |
WO2013053034A3 (pt) | Tiazacridinas utilizadas na terapia anticâncer |